<div class="article-image">
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-25-02-2026-shutterstock_2284571133-430x241.jpg"/>
                                    
                                    <figcaption>SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders. Credit: Komsan Loonprom / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.</p>



<p>The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong).</p><div class="mpu-ad-container">
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div class="in-article-premium-insights mobile-useragent-scalar"><div class="cell large-2 sidebar-scalar mobile-only">
                   <div class="gdm-widget gdm-recommended-reports gdm-pi-recommended-reports gdm-orange-banner recommended-whitepapers"><h3>Go deeper with GlobalData</h3><ul><li><div class="cell small-2"><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div class="cell small-10 details"><div class="category">Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - SL-172154 in Myelodysplastic Syndrome </h4></div> </li><li><div class="cell small-2"><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div class="cell small-10 details"><div class="category">Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - SL-172154 in Refractory Acute Myeloid Leukemia </h4></div> </li></ul> <div class="about-premium-insights">
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The company is headed by CEO and board director Gregory Oakes, who brings more than 30 years of experience from clinical-stage and commercial biopharma organisations.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Oakes previously worked as a venture partner at Raven, RA Capital’s healthcare arm, and held executive roles at Celgene, Landos Biopharma, Vifor Pharma, and Novartis.</p>



<p>Neil Buckley has joined as COO and president after serving as a venture partner at Raven. The clinical team includes chief medical officer Roger Cady, a specialist in headache medicine and former neurology vice-president at Alder Biopharmaceuticals.</p>



<p>Also referred to as DS009, SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders.</p><div class="gdm-company-profile-unit"> 
                         <div class="gdm-company-profile-unit__profile-container">


            <div class="gdm-company-profile-unit__image-container report-cover" style="width: auto; height: auto">

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div class="gdm-company-profile-unit__form-container">

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper" class="gdm-company-profile-unit__form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>PACAP is considered a distinct clinically validated target compared to calcitonin gene-related peptide (CGRP), possibly offering benefits for those not effectively treated by current therapies.</p>



<p>SLTE-1009 incorporates half-life extension technology, allowing for subcutaneous dosing. Slate Medicines is also developing another pipeline project, details of which have not yet been disclosed.</p><div id="slot-two"></div>



<p>Oakes said: “With compelling biology, a differentiated product profile, and strong investor backing, Slate Medicines is positioned to redefine migraine prevention for patients who need new options.</p>



<p>“We believe that SLTE-1009 not only offers patients a novel mechanism for migraine prevention but also improved access through convenient at-home subcutaneous dosing.”</p>



<p>Cady said: “PACAP blockade represents a clinically validated approach for the prevention of migraine headaches. For the millions of patients with an inadequate response to the existing standard of care, we believe that SLTE-1009 offers a novel, orthogonal approach to preventing migraines.”</p>



<p>Andrew Levin (RA Capital), Tim Lohoff (Forbion), and Cindy Xiong (Foresite Capital) will join Slate Medicines’ Board of Directors following this financing round.</p>
<div id="slot-three"></div><p></p>



<div class="grid-container">
    
</div>




VRTX

SLRX

BPMC

<p>Slate Medicines has raised $130 million in a Series A financing round to advance its anti-PACAP migraine therapies, specifically the monoclonal antibody SLTE-1009. This funding follows the in-licensing of SLTE-1009 from DartsBio Pharmaceuticals. The company aims to provide a novel mechanism for migraine prevention, targeting patients who do not respond well to existing treatments. CEO Gregory Oakes emphasized the potential of SLTE-1009 for improved patient access through convenient subcutaneous dosing. The financing round also brings new members to the Board of Directors from RA Capital, Forbion, and Foresite Capital.</p>

Pharmaceutical Technology

Vertex Pharma

Salarius Pharmaceuticals

Blueprint Med

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Slate Medicines raises $130m in funds to progress anti-PACAP treatments